103878-83-7,MFCD00878458
Catalog No.:AA00856H

103878-83-7 | Lazabemide hydrochloride

Pack Size
Purity
Availability
Price(USD)
Quantity
  
10mg
≥98%(HPLC)
in stock  
$277.00   $194.00
- +
50mg
≥98%(HPLC)
in stock  
$941.00   $659.00
- +
250mg
≥98%(HPLC)
in stock  
$4,036.00   $2,825.00
- +
  • Technical Information
  • Properties
  • Downstream Synthesis Route
  • Literature
  • Request for Quotation
  • Download SDS
Technical Information
Catalog Number:
AA00856H
Chemical Name:
Lazabemide hydrochloride
CAS Number:
103878-83-7
Molecular Formula:
C8H11Cl2N3O
Molecular Weight:
236.0984
MDL Number:
MFCD00878458
SMILES:
NCCNC(=O)c1ccc(cn1)Cl.Cl
Properties
Computed Properties
 
Complexity:
177  
Covalently-Bonded Unit Count:
2  
Heavy Atom Count:
14  
Hydrogen Bond Acceptor Count:
3  
Hydrogen Bond Donor Count:
3  
Rotatable Bond Count:
3  

Downstream Synthesis Route

[1]CurrentPatentAssignee:RENAISSANCEMEDICINE-WO2008/10796,2008,A1Locationinpatent:Page/Pagecolumn15-16

[2]CurrentPatentAssignee:RENAISSANCEMEDICINE-WO2008/10796,2008,A1Locationinpatent:Page/Pagecolumn18

[3]CurrentPatentAssignee:RENAISSANCEMEDICINE-WO2008/10796,2008,A1Locationinpatent:Page/Pagecolumn17

[4]CurrentPatentAssignee:RENAISSANCEMEDICINE-WO2008/10794,2008,A1Locationinpatent:Page/Pagecolumn12-13

[5]CurrentPatentAssignee:RENAISSANCEMEDICINE-WO2008/10794,2008,A1Locationinpatent:Page/Pagecolumn11

[1]CurrentPatentAssignee:ROCHEHOLDINGAG-US4764522,1988,A

Literature

Title: Pharmacological characterization of MRZ-8676, a novel negative allosteric modulator of subtype 5 metabotropic glutamate receptors (mGluR5): focus on L: -DOPA-induced dyskinesia.

Journal: Journal of neural transmission (Vienna, Austria : 1996) 20111201

Title: Combined treatment with MAO-A inhibitor and MAO-B inhibitor increases extracellular noradrenaline levels more than MAO-A inhibitor alone through increases in beta-phenylethylamine.

Journal: European journal of pharmacology 20100710

Title: Molecular dynamics, flexible docking, virtual screening, ADMET predictions, and molecular interaction field studies to design novel potential MAO-B inhibitors.

Journal: Journal of biomolecular structure & dynamics 20080201

Title: Autoradiographical distribution of imidazoline binding sites in monoamine oxidase A deficient mice.

Journal: Journal of neurochemistry 20060301

Title: Effect of co-administration of subchronic lithium pretreatment and acute MAO inhibitors on extracellular monoamine levels and the expression of contextual conditioned fear in rats.

Journal: European journal of pharmacology 20060227

Title: Characterisation of imidazoline I2 binding sites in pig brain.

Journal: European journal of pharmacology 20050905

Title: High-affinity binding of beta-carbolines to imidazoline I2B receptors and MAO-A in rat tissues: norharman blocks the effect of morphine withdrawal on DOPA/noradrenaline synthesis in the brain.

Journal: European journal of pharmacology 20050822

Title: Monoamine oxidase B inhibitors for early Parkinson's disease.

Journal: The Cochrane database of systematic reviews 20050720

Title: Effects of depression, cigarette smoking, and age on monoamine oxidase B in amygdaloid nuclei.

Journal: Brain research 20050510

Title: Clinical trials of neuroprotection for Parkinson's disease.

Journal: Neurology 20041012

Title: Serotonin transporter and MAO-B levels in monoamine nuclei of the human brainstem are normal in major depression.

Journal: Journal of psychiatric research 20030101

Title: Lazabemide, a selective, reversible monoamine oxidase B inhibitor, as an aid to smoking cessation.

Journal: Addiction (Abingdon, England) 20021001

Title: Lifestyle drug market booming.

Journal: Nature medicine 20020901

Title: Inhibition of monoamine oxidase modulates the behaviour of semicarbazide-sensitive amine oxidase (SSAO).

Journal: Journal of neural transmission (Vienna, Austria : 1996) 20020301

Title: Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism.

Journal: European journal of pharmacology 20010518

Title: Antioxidant activity of the monoamine oxidase B inhibitor lazabemide.

Journal: Biochemical pharmacology 20000901

Title: Safety study of lazabemide (Ro19-6327), a new MAO-B inhibitor, on cardiac arrhythmias and blood pressure of patients with Parkinson's disease.

Journal: Clinical neuropharmacology 19990101

Title: Effect of lazabemide on the progression of disability in early Parkinson's disease. The Parkinson Study Group.

Journal: Annals of neurology 19960701

Title: Molecular neuroanatomy of human monoamine oxidases A and B revealed by quantitative enzyme radioautography and in situ hybridization histochemistry.

Journal: Neuroscience 19960201

Title: Increased monoamine oxidase B activity in plaque-associated astrocytes of Alzheimer brains revealed by quantitative enzyme radioautography.

Journal: Neuroscience 19940901

Title: Lazabemide (Ro 19-6327), a reversible and highly sensitive MAO-B inhibitor: preclinical and clinical findings.

Journal: Journal of neural transmission. Supplementum 19940101

Title: Monoamine oxidase B (MAO B) inhibitor therapy in Parkinson's disease: the degree and reversibility of human brain MAO B inhibition by Ro 19 6327.

Journal: Neurology 19931001

Title: Ro 19-6327, a reversible and highly selective monoamine, oxidase B inhibitor: a novel tool to explore the MAO-B function in humans.

Journal: Advances in neurology 19900101

Title: Saura J, et al. Quantitative enzyme radioautography with 3H-Ro 41-1049 and 3H-Ro 19-6327 in vitro: localization and abundance of MAO-A and MAO-B in rat CNS, peripheral organs, and human brain. J Neurosci. 1992 May;12(5):1977-99.

Title: Bondiolotti GP, et al. In vitro effects on monoamine uptake and release by the reversible monoamine oxidase-B inhibitors lazabemide and N-(2-aminoethyl)-p-chlorobenzamide: a comparison with L-deprenyl. Biochem Pharmacol. 1995 Jun 29;50(1):97-102.

Title: Guimaraes J, et al. The activity of MAO A and B in rat renal cells and tubules. Life Sci. 1998;62(8):727-37.

Title: Suzuki T, et al. MAO inhibitors, clorgyline and lazabemide, prevent hydroxyl radical generation caused by brain ischemia/reperfusion in mice. Pharmacology. 1995 Jun;50(6):357-62.

Quotation Request
Company Name:
*
Contact Person:
*
Email:
*
Quantity Required:
*
Country:
Additional Info:
SDS
Tags:103878-83-7 Molecular Formula|103878-83-7 MDL|103878-83-7 SMILES|103878-83-7 Lazabemide hydrochloride
Catalog No.: AA00856H
103878-83-7,MFCD00878458
103878-83-7 | Lazabemide hydrochloride
Pack Size: 10mg
Purity: ≥98%(HPLC)
in stock
$277.00 $194.00
Pack Size: 50mg
Purity: ≥98%(HPLC)
in stock
$941.00 $659.00
Pack Size: 250mg
Purity: ≥98%(HPLC)
in stock
$4,036.00 $2,825.00
Quantity
- +
Add to Card
Order Now
bulk Quotation Request
Technical Information
Catalog Number: AA00856H
Chemical Name: Lazabemide hydrochloride
CAS Number: 103878-83-7
Molecular Formula: C8H11Cl2N3O
Molecular Weight: 236.0984
MDL Number: MFCD00878458
SMILES: NCCNC(=O)c1ccc(cn1)Cl.Cl
Properties
Complexity: 177  
Covalently-Bonded Unit Count: 2  
Heavy Atom Count: 14  
Hydrogen Bond Acceptor Count: 3  
Hydrogen Bond Donor Count: 3  
Rotatable Bond Count: 3  
Downstream Synthesis Route
103878-84-8    103878-83-7 

[1]CurrentPatentAssignee:RENAISSANCEMEDICINE-WO2008/10796,2008,A1Locationinpatent:Page/Pagecolumn15-16

[2]CurrentPatentAssignee:RENAISSANCEMEDICINE-WO2008/10796,2008,A1Locationinpatent:Page/Pagecolumn18

[3]CurrentPatentAssignee:RENAISSANCEMEDICINE-WO2008/10796,2008,A1Locationinpatent:Page/Pagecolumn17

[4]CurrentPatentAssignee:RENAISSANCEMEDICINE-WO2008/10794,2008,A1Locationinpatent:Page/Pagecolumn12-13

[5]CurrentPatentAssignee:RENAISSANCEMEDICINE-WO2008/10794,2008,A1Locationinpatent:Page/Pagecolumn11

103878-82-6    103878-83-7 

[1]CurrentPatentAssignee:ROCHEHOLDINGAG-US4764522,1988,A

Literature fold

Title: Pharmacological characterization of MRZ-8676, a novel negative allosteric modulator of subtype 5 metabotropic glutamate receptors (mGluR5): focus on L: -DOPA-induced dyskinesia.

Journal: Journal of neural transmission (Vienna, Austria : 1996)20111201

Title: Combined treatment with MAO-A inhibitor and MAO-B inhibitor increases extracellular noradrenaline levels more than MAO-A inhibitor alone through increases in beta-phenylethylamine.

Journal: European journal of pharmacology20100710

Title: Molecular dynamics, flexible docking, virtual screening, ADMET predictions, and molecular interaction field studies to design novel potential MAO-B inhibitors.

Journal: Journal of biomolecular structure & dynamics20080201

Title: Autoradiographical distribution of imidazoline binding sites in monoamine oxidase A deficient mice.

Journal: Journal of neurochemistry20060301

Title: Effect of co-administration of subchronic lithium pretreatment and acute MAO inhibitors on extracellular monoamine levels and the expression of contextual conditioned fear in rats.

Journal: European journal of pharmacology20060227

Title: Characterisation of imidazoline I2 binding sites in pig brain.

Journal: European journal of pharmacology20050905

Title: High-affinity binding of beta-carbolines to imidazoline I2B receptors and MAO-A in rat tissues: norharman blocks the effect of morphine withdrawal on DOPA/noradrenaline synthesis in the brain.

Journal: European journal of pharmacology20050822

Title: Monoamine oxidase B inhibitors for early Parkinson's disease.

Journal: The Cochrane database of systematic reviews20050720

Title: Effects of depression, cigarette smoking, and age on monoamine oxidase B in amygdaloid nuclei.

Journal: Brain research20050510

Title: Clinical trials of neuroprotection for Parkinson's disease.

Journal: Neurology20041012

Title: Serotonin transporter and MAO-B levels in monoamine nuclei of the human brainstem are normal in major depression.

Journal: Journal of psychiatric research20030101

Title: Lazabemide, a selective, reversible monoamine oxidase B inhibitor, as an aid to smoking cessation.

Journal: Addiction (Abingdon, England)20021001

Title: Lifestyle drug market booming.

Journal: Nature medicine20020901

Title: Inhibition of monoamine oxidase modulates the behaviour of semicarbazide-sensitive amine oxidase (SSAO).

Journal: Journal of neural transmission (Vienna, Austria : 1996)20020301

Title: Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism.

Journal: European journal of pharmacology20010518

Title: Antioxidant activity of the monoamine oxidase B inhibitor lazabemide.

Journal: Biochemical pharmacology20000901

Title: Safety study of lazabemide (Ro19-6327), a new MAO-B inhibitor, on cardiac arrhythmias and blood pressure of patients with Parkinson's disease.

Journal: Clinical neuropharmacology19990101

Title: Effect of lazabemide on the progression of disability in early Parkinson's disease. The Parkinson Study Group.

Journal: Annals of neurology19960701

Title: Molecular neuroanatomy of human monoamine oxidases A and B revealed by quantitative enzyme radioautography and in situ hybridization histochemistry.

Journal: Neuroscience19960201

Title: Increased monoamine oxidase B activity in plaque-associated astrocytes of Alzheimer brains revealed by quantitative enzyme radioautography.

Journal: Neuroscience19940901

Title: Lazabemide (Ro 19-6327), a reversible and highly sensitive MAO-B inhibitor: preclinical and clinical findings.

Journal: Journal of neural transmission. Supplementum19940101

Title: Monoamine oxidase B (MAO B) inhibitor therapy in Parkinson's disease: the degree and reversibility of human brain MAO B inhibition by Ro 19 6327.

Journal: Neurology19931001

Title: Ro 19-6327, a reversible and highly selective monoamine, oxidase B inhibitor: a novel tool to explore the MAO-B function in humans.

Journal: Advances in neurology19900101

Title: Saura J, et al. Quantitative enzyme radioautography with 3H-Ro 41-1049 and 3H-Ro 19-6327 in vitro: localization and abundance of MAO-A and MAO-B in rat CNS, peripheral organs, and human brain. J Neurosci. 1992 May;12(5):1977-99.

Title: Bondiolotti GP, et al. In vitro effects on monoamine uptake and release by the reversible monoamine oxidase-B inhibitors lazabemide and N-(2-aminoethyl)-p-chlorobenzamide: a comparison with L-deprenyl. Biochem Pharmacol. 1995 Jun 29;50(1):97-102.

Title: Guimaraes J, et al. The activity of MAO A and B in rat renal cells and tubules. Life Sci. 1998;62(8):727-37.

Title: Suzuki T, et al. MAO inhibitors, clorgyline and lazabemide, prevent hydroxyl radical generation caused by brain ischemia/reperfusion in mice. Pharmacology. 1995 Jun;50(6):357-62.

Building Blocks More >
1032229-33-6
1032229-33-6
A939572
AA0085UY | MFCD10698997
89282-70-2
89282-70-2
2-Methoxy-2-methylpropan-1-amine
AA0087DE | MFCD01821229
887267-53-0
887267-53-0
Ethyl 3-(2,5-difluorophenyl)-3-oxopropanoate
AA0088Z4 | MFCD07783808
886510-13-0
886510-13-0
1-Fmoc-3-hydroxyazetidine
AA008A1Q | MFCD08437604
887587-50-0
887587-50-0
methyl 6-bromo-4-chloroquinoline-2-carboxylate
AA008BBE | MFCD07783793
878437-11-7
878437-11-7
4-(3-(Pyridin-3-yl)-1,2,4-oxadiazol-5-yl)butanoic acid
AA008CI8 | MFCD07186540
87051-43-2
87051-43-2
RITANSERIN
AA008DMV | MFCD00069341
875-59-2
875-59-2
4'-Hydroxy-2'-methylacetophenone
AA008ETJ | MFCD00002303
85342-65-0
85342-65-0
4,5,6,7-Tetrachloro-2-hydroxyisoindoline-1,3-dione
AA008FE8 | MFCD29088000
864674-02-2
864674-02-2
1-(2-Bromopyridin-4-yl)ethanone
AA008G2B | MFCD07367876
Submit
© 2017 AA BLOCKS, INC. All rights reserved.